Revenio Group Corporation | Stock Exchange Release | February 21, 2024 at 10:30:00 EET

Person subject to the notification requirement
Name: John Floyd
Position: Other senior manager

Issuer: Revenio Group Oyj
LEI: 743700I27E0FWSXLKK04
Notification type: INITIAL NOTIFICATION
Reference number: 52997/5/4

Transaction date: 2024-02-20
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009010912
Nature of transaction: DISPOSAL

Transaction details (1):
Volume: 835 Unit price: 26.5 EUR

Aggregated transactions (1):
Volume: 835 Volume weighted average price: 26.5 EUR

For further information, please contact
CFO Robin Pulkkinen, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi

Distribution
Nasdaq Helsinki
FIN-FSA
Key media
www.reveniogroup.fi

Revenio Group in brief
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand.

In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

Revenio Group Corporation: Managers' Transactions – John Floyd

© Modular Finance, source Nordic Press Releases